Cancer Research Versailles No Abst  Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, H.
Right arrow Articles by Cabot, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, H.
Right arrow Articles by Cabot, M. C.
[Cancer Research 61, 5102-5105, July 1, 2001]
© 2001 American Association for Cancer Research


Experimental Therapeutics

N-(4-Hydroxyphenyl)retinamide Elevates Ceramide in Neuroblastoma Cell Lines by Coordinate Activation of Serine Palmitoyltransferase and Ceramide Synthase1

Hongtao Wang, Barry J. Maurer, C. Patrick Reynolds and Myles C. Cabot2

John Wayne Cancer Institute at Saint John’s Health Center, Santa Monica, California 90404 [H. W., M. C. C.]; Division of Hematology-Oncology, Children’s Hospital, Los Angeles, California 90027 [B. J. M., C. P. R.]; and Departments of Pediatrics [B. J. M., C. P. R.], Cell and Neurobiology [B. J. M.], and Pathology [C. P. R.], University of Southern California Keck School of Medicine, Los Angeles, California 90033

The retinoid N-(4-hydroxyphenyl)retinamide (4-HPR; fenretinide) is cytotoxic to a variety of cancer cell lines, and we previously showed an association between ceramide generation and 4-HPR cytotoxicity for neuroblastoma cell lines (B. J. Maurer et al., J. Natl. Cancer Inst. (Bethesda), 91: 1138–1146, 1999). Here we determine whether the increased ceramide mediated by 4-HPR in the CHLA-90 human neuroblastoma cell line results from de novo ceramide synthesis. Treatment of CHLA-90 with 4-HPR for 2 h, in the presence of [3H]palmitic acid, caused sequential formation of [3H]sphinganine (220% over control) and [3H]ceramide (160% over control), with sphinganine returning to baseline at 4 h, and ceramide continuing to increase (215% over control). 4-HPR treatment did not accelerate cellular decay of sphingomyelin. Preincubation of cells with either L-cycloserine, an inhibitor of serine palmitoyltransferase (SPT), or fumonisin B1, an inhibitor of ceramide synthase, retarded ceramide formation in response to 4-HPR treatment, although sphinganine was still generated when 4-HPR and FB1 were present. Data from in vitro enzyme assays using microsomes showed that preexposure of intact cells to 4-HPR resulted in a time (175% over control; 6 h)- and dose-dependent increase (173% over control; 10 µM) in SPT activity as well as a time (265% over control)- and dose-dependent increase (215% above control; 10 µM) in ceramide synthase activity. Our results show that 4-HPR-mediated ceramide generation is derived from the de novo synthetic pathway by coordinate activation of SPT and ceramide synthase. Knowledge of these biochemical events is of utility when downstream modulators of ceramide metabolism are used to heighten the cytotoxic response to chemotherapy.




This article has been cited by other articles:


Home page
J. Lipid Res.Home page
S. Schiffmann, J. Sandner, R. Schmidt, K. Birod, I. Wobst, H. Schmidt, C. Angioni, G. Geisslinger, and S. Grosch
The selective COX-2 inhibitor celecoxib modulates sphingolipid synthesis
J. Lipid Res., January 1, 2009; 50(1): 32 - 40.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
D. E. Saslowsky, N. Tanaka, K. P. Reddy, and W. I. Lencer
Ceramide activates JNK to inhibit a cAMP-gated K+ conductance and Cl- secretion in intestinal epithelia
FASEB J, January 1, 2009; 23(1): 259 - 270.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
H. Wang, B. J. Maurer, Y.-Y. Liu, E. Wang, J. C. Allegood, S. Kelly, H. Symolon, Y. Liu, A. H. Merrill, Jr., V. Gouaze-Andersson, et al.
N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing
Mol. Cancer Ther., September 1, 2008; 7(9): 2967 - 2976.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
S. T. Pruett, A. Bushnev, K. Hagedorn, M. Adiga, C. A. Haynes, M. C. Sullards, D. C. Liotta, and A. H. Merrill Jr.
Thematic Review Series: Sphingolipids. Biodiversity of sphingoid bases ("sphingosines") and related amino alcohols
J. Lipid Res., August 1, 2008; 49(8): 1621 - 1639.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
P. G. Sreekumar, J. Zhou, J. Sohn, C. Spee, S. J. Ryan, B. J. Maurer, R. Kannan, and D. R. Hinton
N-(4-hydroxyphenyl) Retinamide Augments Laser-Induced Choroidal Neovascularization in Mice
Invest. Ophthalmol. Vis. Sci., March 1, 2008; 49(3): 1210 - 1220.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. M. Kraveka, L. Li, Z. M. Szulc, J. Bielawski, B. Ogretmen, Y. A. Hannun, L. M. Obeid, and A. Bielawska
Involvement of Dihydroceramide Desaturase in Cell Cycle Progression in Human Neuroblastoma Cells
J. Biol. Chem., June 8, 2007; 282(23): 16718 - 16728.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. G. Villani, V. Appierto, E. Cavadini, A. Bettiga, A. Prinetti, M. Clagett-Dame, R. W. Curley, and F. Formelli
4-Oxo-Fenretinide, a Recently Identified Fenretinide Metabolite, Induces Marked G2-M Cell Cycle Arrest and Apoptosis in Fenretinide-Sensitive and Fenretinide-Resistant Cell Lines.
Cancer Res., March 15, 2006; 66(6): 3238 - 3247.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Schulz, T. Mousallem, M. Venkataramani, D.-A. Persaud-Sawin, A. Zucker, C. Luberto, A. Bielawska, J. Bielawski, J. C. M. Holthuis, S. M. Jazwinski, et al.
The CLN9 Protein, a Regulator of Dihydroceramide Synthase
J. Biol. Chem., February 3, 2006; 281(5): 2784 - 2794.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. Y. Park, A. Dillard, E. A. Williams, E. T. Wilder, M. R. Pepper, and M. A. Lane
Retinol Inhibits the Growth of All-Trans-Retinoic Acid-Sensitive and All-Trans-Retinoic Acid-Resistant Colon Cancer Cells through a Retinoic Acid Receptor-Independent Mechanism
Cancer Res., November 1, 2005; 65(21): 9923 - 9933.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
E. A. Sausville
Indifferently Pursued or Unowned Drugs: Who Should Lead Where Companies Do Not Tread?
J. Clin. Oncol., March 20, 2005; 23(9): 1796 - 1798.
[Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
C. M. Finnegan, S. S. Rawat, A. Puri, J. M. Wang, F. W. Ruscetti, and R. Blumenthal
Ceramide, a target for antiretroviral therapy
PNAS, October 26, 2004; 101(43): 15452 - 15457.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
P. E. Lovat, F. Di Sano, M. Corazzari, B. Fazi, R. P. Donnorso, A. D. J. Pearson, A. G. Hall, C. P. F. Redfern, and M. Piacentini
Gangliosides Link the Acidic Sphingomyelinase-Mediated Induction of Ceramide to 12-Lipoxygenase-Dependent Apoptosis of Neuroblastoma in Response to Fenretinide
J Natl Cancer Inst, September 1, 2004; 96(17): 1288 - 1299.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Prinetti, L. Basso, V. Appierto, M. G. Villani, M. Valsecchi, N. Loberto, S. Prioni, V. Chigorno, E. Cavadini, F. Formelli, et al.
Altered Sphingolipid Metabolism in N-(4-Hydroxyphenyl)- retinamide-resistant A2780 Human Ovarian Carcinoma Cells
J. Biol. Chem., February 14, 2003; 278(8): 5574 - 5583.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Erdreich-Epstein, L. B. Tran, N. N. Bowman, H. Wang, M. C. Cabot, D. L. Durden, J. Vlckova, C. P. Reynolds, M. F. Stins, S. Groshen, et al.
Ceramide Signaling in Fenretinide-induced Endothelial Cell Apoptosis
J. Biol. Chem., December 13, 2002; 277(51): 49531 - 49537.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
G. M. Jenkins, L. A. Cowart, P. Signorelli, B. J. Pettus, C. E. Chalfant, and Y. A. Hannun
Acute Activation of de Novo Sphingolipid Biosynthesis upon Heat Shock Causes an Accumulation of Ceramide and Subsequent Dephosphorylation of SR Proteins
J. Biol. Chem., November 1, 2002; 277(45): 42572 - 42578.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
H. Wang, A. E. Giuliano, and M. C. Cabot
Enhanced de Novo Ceramide Generation through Activation of Serine Palmitoyltransferase by the P-Glycoprotein Antagonist SDZ PSC 833 in Breast Cancer Cells
Mol. Cancer Ther., July 1, 2002; 1(9): 719 - 726.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.